Stockreport

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p Patients in the RADIANT study of vormatrigine showed rapid, [Read more]